Loading provider…
Loading provider…
Hematology & Oncology Physician in Philadelphia, PA
NPI: 1457598930Primary Practice Location
PENNSYLVANIA HOSPITAL
800 Spruce St, Philadelphia, PA
Primary Employer
Perelman Center for Advanced Medicine
pennmedicine.org
HQ Phone
Get MD Douglas's Phone Numberphone_androidMobile
Get MD Douglas's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardPA State Medical License
PA State Medical License
2011 - 2026
NJ State Medical License
2009 - 2025

American Board of Internal Medicine
Hematology

American Board of Internal Medicine
Medical Oncology
Cooper Medical School of Rowan University/Cooper University Hospital
Fellowship • Hematology and Medical Oncology
2009 - 2012
Residency • Internal Medicine
2006 - 2009
Rutgers Robert Wood Johnson Medical School
Medical School
Until 2006
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99213Established patient office or other outpatient visit, typically 15 minutes | 185 | 319 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 72 | 108 |
| 3 | 99215Established patient office or other outpatient, visit typically 40 minutes | 40 | 98 |
| 4 | 99204New patient office or other outpatient visit, 45-59 minutes | 35 | 35 |
| 5 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 29 | 76 |
Distinct LIN-10 Domains Are Required for Its Neuronal Function, Its Epithelial Function, and Its Synaptic Localization
Authors: Doreen R. Glodowski, Tricia Wright, Keri Martinowich, Howard C. Chang, Douglas F. Beach, Christopher Rongo
Publication Date: 2005-01
Metastatic renal cell carcinoma to the phalanx.
Authors: Robert Somer
Publication Date: 2011-08-08
Metastatic Renal Cell Carcinoma to the Phalanx
Authors: Beach, Douglas F, Somer, Robert
Journal: Urology
Publication Date: 2011-11-23
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: OTHER: Laboratory Biomarker Analysis, OTHER: Pharmacological Study, BIOLOGICAL: Pegfilgrastim, DRUG: Cyclophosphamide, DRUG: Ibrutinib, DRUG: Prednisone, DRUG: Etoposide, DRUG: Vincristine Sulfate, BIOLOGICAL: Rituximab, BIOLOGICAL: Filgrastim, DRUG: Doxorubicin Hydrochloride
Lead Sponsor: TG Therapeutics, Inc.
Intervention / Treatment: BIOLOGICAL: Ublituximab, DRUG: Umbralisib, BIOLOGICAL: Bendamustine
Lead Sponsor: TG Therapeutics, Inc.
Intervention / Treatment: DRUG: Chlorambucil, BIOLOGICAL: Ublituximab, BIOLOGICAL: Obinutuzumab, DRUG: TGR-1202